S100B protects LAN‐5 neuroblastoma cells against Aβ amyloid‐induced neurotoxicity via RAGE engagement at low doses but increases Aβ amyloid neurotoxicity at high doses
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
At the concentrations normally found in the brain extracellular space the glial‐derived protein, S100B, protects neurons against neurotoxic agents by interacting with the receptor for advanced glycation end products (RAGE). It is known that at relatively high concentrations S100B is neurotoxic causing neuronal death via excessive stimulation of RAGE. S100B is detected within senile plaques in Alzheimer's disease, where its role is unknown. The present study was undertaken to evaluate a putative neuroprotective role of S100B against Aβ amyloid‐induced neurotoxicity. We treated LAN‐5 neuroblastoma cultures with toxic amounts of Aβ25‐35 amyloid peptide. Our results show that at nanomolar concentrations S100B protects cells against Aβ‐mediated cytotoxicity, as assessed by 3‐(4,5‐dimethyl‐thiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) and terminal deoxynucleotidyl transferase‐mediated dUTP‐fluorescein isothiocyanate nick end‐labeling (TUNEL) experiments, by countering the Aβ‐mediated decrease in the expression of the anti‐apoptotic factor Bcl‐2. This effect depends on S100B binding to RAGE because S100B is unable to contrast Aβ‐mediated neurotoxicity in neurons overexpressing a signaling‐deficient RAGE mutant lacking the cytosolic and transducing domain. Our data suggest that at nanomolar doses S100B counteracts Aβ peptide neurotoxicity in a RAGE‐mediated manner. However, at micromolar doses S100B is toxic to LAN‐5 cells and its toxicity adds to that of the Aβ peptide, suggesting that additional molecular mechanisms may be involved in the neurotoxic process. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 2×
“Previous work has shown that RAGE binds Ab peptide (Yan et al., 1996), thereby mediating transcytosis of circulating Ab peptide into the brain, whereas LRP clears brain Ab peptide into the blood (Deane et al., 2004).”
BackgroundNeurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides
Yankner, B. A., Duffy, L. K., & Kirschner, D. A. (1990) · Science · doi:10.1126/science.2218531 · Cited by 1,975 · cited 1×
“This peptide, which is 39–43 amino acids in length, harbors a neurotoxic domain restricted to the 25–35 region (Yankner et al., 1990).”
BackgroundDonato, R. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00046-2 · Cited by 1,580
Self-citationIntracellular and extracellular roles of S100 proteins
Donato, R. (2003) · Microscopy Research and Technique · doi:10.1002/jemt.10296 · Cited by 974 · cited 2×
“…Inc. Key words: Alzheimer’s disease; neuroprotection; Bcl-2; sRAGE; ERK1/2 S100B is a member of the S100 family of EF-hand Ca2þ binding protein, mainly expressed in astrocytes in the central nervous system, exerting intracellular and extra- cellular regulatory activities (Donato, 2001, 2003).”
BackgroundSelf-citationAllan Butterfield, D. (2002) · Free Radical Research · doi:10.1080/1071576021000049890 · Cited by 786
Pike, C. J., Walencewicz‐Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., & Cotman, C. W. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010253.x · Cited by 699
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561 · cited 4×
“Amyloid-b (Ab) peptide, derived from the proteolytic fragmentation of the amyloid precursor protein (APP), is the main component of extracellular senile plaques detected in the brain of AD patients.”
BackgroundResultInfluentialDeane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392
Ishihara, K., Tsutsumi, K., Kawane, S., Nakajima, M., & Kasaoka, T. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00846-9 · Cited by 201
Kögel, D., Peters, M., König, H.-G., Hashemi, S. M. A., Bui, N. T., Arolt, V., Rothermundt, M., & Prehn, J. H. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.013 · Cited by 82 · cited 8×
“…of Journal of Neuroscience Research DOI 10.1002/jnr ERK1/2 and upregulation of Bcl-2 expression (Huttunen et al., 2000; Ishihara et al., 2003; Kogel et al., 2004), we treated LAN-5 cells for 60 min with 10 lM U0126, a specific inhibitor of the ERK1/2 upstream kinase, MEK, followed by the…”
BackgroundMethodResultInfluential
Cited by
Donato, R., R. Cannon, B., Sorci, G., Riuzzi, F., Hsu, K., J. Weber, D., & L. Geczy, C. (2013) · Current Molecular Medicine · doi:10.2174/156652413804486214 · Cited by 1,316
Self-citationS100B's double life: Intracellular regulator and extracellular signal
Donato, R., Sorci, G., Riuzzi, F., Arcuri, C., Bianchi, R., Brozzi, F., Tubaro, C., & Giambanco, I. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.009 · Cited by 731
Self-citationSparvero, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., Rutledge, R., Lin, B., Amoscato, A. A., Zeh, H. J., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-17 · Cited by 622
Binding of S100 proteins to RAGE: An update
Leclerc, E., Fritz, G., Vetter, S. W., & Heizmann, C. W. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.11.016 · Cited by 489
The S100B story: from biomarker to active factor in neural injury
Michetti, F., D'Ambrosi, N., Toesca, A., Puglisi, M. A., Serrano, A., Marchese, E., Corvino, V., & Geloso, M. C. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14574 · Cited by 410
Metadata
- Authors
- Businaro, R., Leone, S., Fabrizi, C., Sorci, G., Donato, R., Lauro, G. M., & Fumagalli, L.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2006-02-13
- Volume
- 83
- Issue
- 5
- Pages
- 897-906
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W1994406619
- Cited by
- 95
- References
- 10
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.